Sixteen millions of people are diabetics in the United States. Finding an oral way to deliver the insulin they need would improve the quality of their life. For this purpose biodegradable and biocompatible nanovesicles encapsulating some insulin have been synthesized. Those nanovesicles are made by self-assembly of a triblock copolymer poly(ethylene glycol)-bpoly( lactic acid)-b-poly(glutamic acid) (PEG-b-PLA-b-PGlu). The triblock copolymer has been prepared in several steps by multi-step anionic ringopening polymerization. The first step consisted in the preparation of the diblock copolymer PEG-b-PLA. This diblock copolymer was synthesized by ring opening of racemic lactide, using a zinc alkoxide as an initiator. The second step was the synthesis of the poly(glutamic acid). The polybenzyl(glutamic acid) was obtained by ring opening polymerization of the N-Carboxyanhydride of the corresponding amino acid. Finally, the benzyl group was deprotected via protonolysis, to generate the homopolymer. This triblock was successfully obtained by coupling a diblock copolymer PEG-bxv PLA and a homopolymer poly(glutamic acid). In the presence of an aqueous solution of insulin where the pH is between 7 and 9, the triblock copolymer self-assembles in nanovesicles containing a part of the free insulin. In the intestine, the vesicles are highly solvated due to the deprotonnated poly(glutamic acid) hair which are expected to be located on the outside. Moreover, to resist from the gastric acidity, the nanovesicles are protected with gastro resistant polymer, Eudragit, which stay solid at acidic pH but get dissolved in the intestine (where the pH is slightly basic), releasing the vesicles. All the polymers have been characterized using 1H NMR and GPC. The percentage of encapsulation of insulin has been measured by HPLC some in-vivo experiments have been done on Sprague-Dawley rats.

This thesis describes evaluation of a gastric retention device (GRD) developed at Oregon State University. The device was originally fabricated from Xanthan gum and Locust bean gum. A modified gastric retention device containing other additives was developed and investigated in this work. The modified device was evaluated in vitro for swelling and dissolution properties using riboflavin as a model drug. Different shapes and sizes of GRDs were tested in dogs to study the gastric retention potential of these devices. The effect of the device on food emptying from the stomach in dogs was also investigated. Endoscopic studies in dogs also showed that the device swells rapidly and considerably in gastric fluid. The bioavailability of riboflavin from three different size GRDs was determined in six fasted human volunteers and compared to an immediate release formulation. The biostudy indicated that the bioavailability of riboflavin from a large size GRD was more than triple that measured after administration of the immediate release formulation. Deconvolution was used to determine gastric residence time of the different size GRDs. A new colonic delivery system made of acetaminophen loaded beads produced by extrusion and spheronization and coated with different ratios of pectin and ethylcellulose coating solutions in a spray coating apparatus was also developed in this work. Such beads release their drug content in the colon due to susceptibility of pectin in the outer coat to enzymatic action of colonic bacteria. The new delivery system was evaluated in vitro by conducting release studies in different dissolution media to mimic transit times, pH and enzyme conditions in the gastrointestinal tract. The gastrointestinal transit behavior of drug beads was also assessed by conducting gamma-scintigraphic studies in dogs. The bioavailability and pharmacokinetic parameters of acetaminophen from several colonic delivery system formulations were determined in human volunteers and compared to the immediate release commercial product Tylenol®. A selected pectin-ethylcellulose coat formulation in the ratio 1:3 was further evaluated in six volunteers under both fed and fasting conditions and was found to be effective and to provide sustained drug release in the colon over a period of 12 hours. / Graduation date: 2003

This thesis describes 1) development of a gastric retention device (GRD) to increase gastric retention time of certain drugs, 2) product formulations of an immediate release itraconazole and controlled-release ketoprofen. GRD was fabricated from crosslinked carbohydrate polymers. Rate and extent of hydration of the film in water and in simulated gastric fluid, compressibility of film, shape of the film, and in vivo gastric transit time in the stomach of dog were used as tools to evaluate gastric retention properties. Hydration studies were carried out at 37��C. Evaluation of the device containing radio-opaque agents, in dogs for gastric retention was carried out with the help of X-rays. The device was found to stay in the stomach of dogs for at least 10 hours. GRD containing amoxicillin trihydrate caplets were evaluated in a human. The area under the excretion rate curve was found to increase by 30% when compared to without the device. A successful development of a formulation of water insoluble itraconazole, without the use of organic solvents, was achieved with modifications from eutectic mixture techniques. Solubilization of the drug was achieved in polyethylene glycol of higher molecular weight. A series of formulations made by varying the amounts ingredients therein, were evaluated for dissolution profile in comparison with the reference, Sporanox��. Effect of molecular weights of PEG and types of PEG were evaluated for desired drug dissolution. Preliminary study from 6 subjects under the conditions of fasting and fed indicated that bioavailability from the new formulation was increased slightly when compared to the reference. This may be correlated to difference in the rate of in vitro dissolution, where the new formulation has initial faster dissolution. A controlled-release formulation of ketoprofen was also developed using a diffusion-controlled polymer, which was coated onto the drug beads. Release of drugs from such beads is controlled by the thickness of the coat. Thickness of the coat was evaluated by SEM and was correlated to the desired in vitro drug release in comparison to the reference Oruvail��. A three-way cross over study involving the new formulation and two marketed products in 12 subjects under fasting conditions indicated that there was a significant difference between the new product and marketed products, so as to be considered non-bioequivalent. Use of In Vitro-In Vivo Correlations and Convolution- Deconvolution relations predicted desired in vitro drug dissolution in a subsequent modification of the formulation. / Graduation date: 1999

Near IR (NIR) sensitive Au-Au₂S nanoparticles were prepared by mixing HAuCl₄ and Na₂S in aqueous solutions. An anti-tumor drug, cis-platin, was adsorbed onto Au-Au₂S nanoparticle surface via the 11-mercaptoundecanoic acid layers. The results showed that the degree of adsorption of cis-platin onto Au-Au₂S nanoparticles was controlled by the pH value of solution, and the drug release was sensitive to NIR irradiation. The cis-platin loaded Au-Au₂S nanoparticles can be potentially applied as NIR activated drug delivery carrier. / Singapore-MIT Alliance (SMA)

Studies of submillimeter gels composed of covalently cross-linked poly(acrylic acid)-g-poly(ethylene oxide)-b-poly(propylene oxide)-b-poly(ethylene oxide) (Pluronic-PAA) networks are reviewed in light of potential applications of the microgels as drug carriers in oral delivery. The microgels are capable of volumetric transitions in response to environmental stimulae such as pH and temperature. It is shown that the type of Pluronic used in the microgel synthesis changes the structure of the resulting microgels, with the more hydrophobic Pluronic imparting porosity. Microgels based on Pluronic L92 (L92-PAA-EGDMA) possess higher ion-exchange capacity than microgels based on Pluronic F127 (F127-PAA-EGDMA), albeit the former are more hydrophobic. Analogously, more hydrophobic but heterogeneous L92-PAA-EGDMA exhibit superior capacity for equilibrium loading of hydrophobic drugs such as taxol, camptothecin and steroid hormones, as well as higher capacity for weakly basic drugs such as doxorubicin, mitomycin C, and mitoxantrone. / Singapore-MIT Alliance (SMA)

A magnetic target drug delivery system consisting of biodegradable polymeric microspheres (poly D, L-lactic acid) loaded with magnetite nanoparticles (10-100 nm) and anticancer drug (paclitaxel) was studied. The magnetite nanoparticles were synthesized by chemical precipitation. The as-synthesized magnetite nanoparticles were subsequently introduced into a mixture of polymer magnetic polymeric composite particles were investigated and further correlated with the reaction parameters. It was found that the size and characteristics of the polymeric composite particles depended on the viscosity of the polymer solution. Preliminary drug release experiments showed that the loaded drug was released with the degradation of the polymer. The release rates could be enhanced by an oscillating external magnetic field. / Singapore-MIT Alliance (SMA)

Thesis (Ph. D.)--University of Rhode Island, 2006. / Typescript. Includes bibliographical references (leaves 210-235).

An in vivo study with 19 rabbits was completed. Half of the exposed rabbits had a magnetic field placed externally over their right lung. Magnetic resonance images of the lungs were acquired to determine the iron concentrations in the right and left lung of each animal. The right/left ratio increased in the middle and basal regions of the lung. With further optimization, this technique could be an effective method for targeted drug delivery. Additionally, the feasibility of increasing the length of high aspect ratio particles for improved targeted drug delivery was explored. An ultrasonic nozzle was pulsed into a large evaporation chamber. Individual particles were found to be double the original length. However, due to locally increased humidity the droplets were not dried, except with the use of an orifice to rapidly accelerate and break apart the larger droplets. The complications associated with this method make it an undesirable and unfeasible method of creating longer particles.

Hydrophobic drug paclitaxel nanoparticles (PAX NPs) and pH sensitive hydrogels were prepared in this study to build a colon targeting nanoparticle based drug delivery system for oral administration. Negative charged PAX NPs at the size of 110 +/- 10 nm were fabricated, characterized and then encapsulated in synthetic / biomacromolecule shell chitosan, dextran-sulfate using a layer by layer (LbL) self-assembly technique. Surface modifications were performed by covalently conjugating with poly (ethylene glycol) (H2N-PEG-carboxymethyl, Mw 3400) and fluorescence labeled wheat germ agglutinin (F-WGA), so as to build a biocompatible and targeted drug delivery system. Extended release of drug paclitaxel can be realized by adding more polyelectrolyte layers in the shell. High cell viability with PEG conjugated and high binding capacities of WGA modified nanoparticles with Caco-2 cells were observed. Preliminary study on stability of the nanoparticles in suspension at different pH was also performed. Two dextran based pH sensitive and enzyme degradable hydrogels: dextran maleic acid (Dex-MA), and glycidyl methacrylated dextran (Dex-GMA) were synthesized for oral delivery of nanoparticles. Hydrogels of both kinds were stable in simulated gastric fluid, but were prone to swelling and degradation in the presence or absence of enzyme dextranase in simulated intestinal fluid. The release profiles of nanoparticles could be tuned from 5 hr to 24 hr periods of time with more than 85% of the nanoparticle released in the simulated intestinal fluid. The release of PAX NPs was completed with longer time periods (45 hr-120 hr). Two possible release mechanisms were discussed for Dex-MA and Dex-GMA-co-AA hydrogels respectively: degradation controlled, and diffusion controlled. These biodegradable hydrogels, which can release nanoparticles depending on pH changes, together with the biocompatible and targeted nanoparticles, may be suitable as a potential colon targeting system for oral delivery of drug nanoparticles.

High molecular weight biomolecules are becoming important in the development of new therapeutics. However, their size and nature creates a major limitation for their application – poor penetration through biological membranes. A new class of peptides, cell-penetrating peptides (CPPs), has shown the capability to transport various macromolecules inside the cells. However, there are at least two limiting factors for successful application of CPPs: the lack of cell-type specificity and restricted bioavailability resulting from endocytic uptake of CPPs and entrapment in endosomal compartments. This thesis aims at designing delivery vehicles for therapeutic substances. In papers I-III, the CPPs have been rationally modified in order to achieve in vivo selectivity towards cancer cells. The first two papers employ tumor homing peptides as targeting moieties coupled to the N-termini of CPPs. In the third paper, a CPP is C-terminally prolonged with a matrix metalloproteinase 2 (MMP-2) specific cleavage site followed by an inactivating amino acid sequence. In tissues overexpressing MMP-2, i. e. in proximity to cancer, the CPP is activated after proteolytic removal of the inactivating sequence, thus the cargo can be transported inside the cells. In paper IV, several CPPs have been N-terminally modified with a stearyl moiety and applied for the delivery of splice-correcting oligonucleotides. We show that stearyl-TP10 is as effective in oligonucleotide delivery as Lipofectamine™ 2000. Moreover, stearyl-TP10 has preserved efficacy in serum and is not toxic to cells. In conclusion, the rational modifications of CPPs greatly potentiate their application in cargo delivery both in vitro and in vivo.